CA
OMIC

Clearstead Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Clearstead Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$1.25K – 1577
2023
Q2 		$1.25K Hold
50
– – ﹤0.01% 1225
2023
Q1 		$1.81K Hold
50
– – ﹤0.01% 1152
2022
Q4 		$3.02K Hold
50
– – ﹤0.01% 1042
2022
Q3 		$4K Hold
50
– – ﹤0.01% 1014
2022
Q2 		$6K Buy
+50
New +$5.86K ﹤0.01% 991

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clearstead Advisors's OMIC Position: Q3 2023 in Review

Clearstead Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2023, closing a stake of 50 shares — an estimated $1.25K sold.

Clearstead Advisors first reported a position in OMIC in Q2 2022 and held it in 5 quarters. The position peaked at $6K in Q2 2022. 48 funds tracked by Wall St. Rank hold OMIC as of Q3 2023.

  • Clearstead Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Clearstead Advisors sold 50 Singular Genomics Systems, Inc. Common Stock shares in Q3 2023, an estimated $1.25K.
  • Clearstead Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Clearstead Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $6K in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2023.

Based on Clearstead Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.